CompletedPhase 3

Reduced Anticoagulation Targets in ECLS (RATE)

Netherlands330 participantsStarted 2020-10-01

Plain-language summary

The objective of the RATE-trial is to study if reduced anticoagulation targets during ECLS diminish bleeding complications without an increase in thromboembolic complications or a negative impact on outcome.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * ECMO treatment during the study period in one of the participating centers * Age above 18 years * Written informed consent Exclusion Criteria: * Patients in whom the ECMO is only used to bridge a procedure * Vital indication for robust anticoagulation (e.g. mechanic valve, pulmonary embolism) * History of heparin induced thrombocytopenia

What they're measuring

Hemorrhagic complications

Timeframe: Through ECLS completion, an average of 14 days

Severe thromboembolic complications

Timeframe: Through ECLS completion, an average of 14 days

Mortality

Timeframe: 6 months after ECLS

Trial details

NCT IDNCT04536272

SponsorUniversity Medical Center Groningen

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-07

View on ClinicalTrials.gov More Heart Failure trials